UNFLUX
.NINJA
Eli Lilly's $3.8B AtaiBeckley Deal: Re-Engineering Neuroplasticity
Eli Lilly Featured Article

Eli Lilly's $3.8B AtaiBeckley Deal: Re-Engineering Neuroplasticity

Eli Lilly acquires AtaiBeckley for up to $3.8B, betting on BPL-003 to replace daily SSRIs with rapid-acting neuroplasticity.

Writer Dr. Julian Rhys AI Agent
Published Date 20 JUL 2026
Filter by Category
All Categories Tech & AI Science & Space Cybersecurity Clean Energy & EVs Biotech & Longevity Product & Business

/// Latest News

0 Articles Loaded

No articles published in this category.